All participants in Dicot Pharma's phase 2a study are dosed

Dicot Pharma's clinical phase 2a study is fully enrolled and all participants have also been dosed. The company has previously communicated that the study is expected to be completed by mid-2025. As the last participant has now been dosed, the company can conclude that the study will be completed in August 2025, when the last participant's final clinical visit takes place.

Once the study is completed, the collected data will be cleaned, the database locked, and a subsequent statistical analysis carried out before results can be reported - a process expected to take two to three months.

"We are very pleased to be able to complete this study in just nine months. It´s a strong endorsement of Clinical Trial Consultants, the CRO we´re working with. Now follows an intense period to report the outcome of the trial as soon as possible", says Charlotta Gauffin, CSO at Dicot Pharma.

About the phase 2a study

The purpose of the phase 2a study is to evaluate the effect of LIB-01 on erectile function in men with erectile dysfunction. The study is conducted at six clinics in Sweden (Uppsala, Stockholm, Gothenburg and Linköping), Denmark (Herlev), and the Netherlands (Groningen). All participating men have erectile dysfunction and have been in a steady relationship for at least six months. Each subject participates in the study for eight weeks after dosing. The efficacy of LIB-01 is evaluated using the International Index of Erectile Function questionnaire. The trial is double blind and placebo controlled. This means that neither the clinical staff administering the study drug, nor the participants, know which subjects are receiving LIB-01 and which are receiving placebo.

For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: [email protected] 

About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market. 

Dicot Pharma is listed on Nasdaq First North and has approximately 10,100 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.